Thor Medical secures 5-year supply deal with NucliThera for thorium-228

Thor Medical ASA announced a five-year frame agreement to supply NucliThera AS with thorium-228 (Th-228), an alpha-emitter crucial for NucliThera's early-stage development programs targeting hematological cancers like lymphoma and leukemia. This supply will originate from AlphaOne, Thor Medical's first commercial-scale isotope production facility, set to commence operations in 2026. This agreement adds to Thor Medical's existing supply commitments for thorium-228 with several partners including Telix Pharmaceuticals and ARTBIO.

NucliThera's research team, led by Dr. Roy H. Larsen and professor emeritus Øyvind S. Bruland, specializes in targeted radionuclide therapies. Dr. Larsen emphasized that reliable access to high-purity alpha-emitters is vital for advancing these development programs. Both Dr. Larsen and Professor Bruland were instrumental in developing Xofigo, an FDA-approved alpha-emitting cancer pharmaceutical that Bayer Healthcare acquired for $2.9 billion in 2014.

The collaboration between Thor Medical and NucliThera extends beyond the supply agreement; in 2023, NucliThera acquired the Nanovector Patents pipeline from Nordic Nanovector, with Thor Medical retaining an undisclosed profit-sharing interest in successful commercialization. Thor Medical, an emerging supplier of radionuclides from naturally occurring thorium, highlights its proprietary production process which avoids irradiation or nuclear reactors, ensuring an environmentally friendly and cost-efficient supply.